790.74

0.70% -5.60

Regeneron Pharmaceuticals Inc (REGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$796.34

Offen:

$803.01

24-Stunden-Volumen:

649.30K

Relative Volume:

1.00

Marktkapitalisierung:

$81.41B

Einnahmen:

$14.92B

Nettoeinkommen (Verlust:

$4.42B

KGV:

19.27

EPS:

41.0422

Netto-Cashflow:

$3.79B

1W Leistung:

+5.92%

1M Leistung:

+2.08%

6M Leistung:

+6.00%

1J Leistung:

+38.93%

1-Tages-Spanne:

$787.32

$805.67

1-Wochen-Bereich:

$743.57

$809.49

52-Wochen-Spanne:

$564.00

$859.34

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals Inc

Sektor

Healthcare (1052)

Branche

Biotechnology (594)

Telefon

(914) 847-7000

Adresse

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Mitarbeiter

15,410

Twitter

@regeneron

Nächster Verdiensttermin

2026-10-30

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Compare REGN vs VRTX, MRNA, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-10-01	Hochstufung	Argus	Hold → Buy
2026-05-18	Herabstufung	Citigroup	Buy → Neutral
2026-05-18	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-03-31	Fortgesetzt	Piper Sandler	Overweight
2026-03-06	Eingeleitet	Barclays	Overweight
2026-01-07	Hochstufung	BofA Securities	Underperform → Buy
2025-12-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Eingeleitet	HSBC Securities	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Perform
2025-08-14	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-30	Herabstufung	Argus	Buy → Hold
2025-05-30	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-14	Hochstufung	Citigroup	Neutral → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-01-16	Herabstufung	UBS	Buy → Neutral
2024-12-10	Fortgesetzt	BofA Securities	Underperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-09-24	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-12	Eingeleitet	Bernstein	Outperform
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

Oct 16, 2026

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types - GlobeNewswire Inc.

Oct 16, 2026

Oct 15, 2026

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research

Oct 15, 2026

Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research

Oct 15, 2026

Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de

Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 13, 2026

Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance

Oct 13, 2026

Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de

Oct 13, 2026

Regeneron presents new long-term data for Pasatru - The Pharma Letter

Oct 13, 2026

Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de

Oct 13, 2026

Oct 12, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 12, 2026

Regeneron’s New Drug Halts Rogue Bone Growth EffectivelyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga

Oct 12, 2026

Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative

Oct 12, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 12, 2026

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits

Oct 12, 2026

Oct 11, 2026

Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street

Oct 11, 2026